<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515345</url>
  </required_header>
  <id_info>
    <org_study_id>IDEAL-PCI protocol 1.0</org_study_id>
    <nct_id>NCT01515345</nct_id>
  </id_info>
  <brief_title>Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry</brief_title>
  <acronym>IDEAL-PCI</acronym>
  <official_title>Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Franz Josef Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Franz Josef Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of a routine individualized
      antiplatelet therapy after coronary stent implantation by evaluating &quot;on-treatment&quot; platelet
      reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depending on the clinical presentation patients are treated according to standard operating
      procedures in our department. The earliest, 12 hours after an initial clopidogrel-loading
      dose (600mg)&quot;on-treatment&quot; platelet reactivity will be determined by Multiple Electrode
      Aggregometry (MEA, Multiplate® Analyzer), a point of care assay. In case of high residual
      platelet reactivity (i.e. ≥ 50U), patients are switched according to a therapeutic algorithm
      to either prasugrel (Efient®), or in case of contraindication (i.e. stroke) to ticagrelor
      (Brilique®), or in case of contraindication (intracranial hemorrhage) reloaded with
      clopidogrel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Definite Stent Thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>The angiographic or pathological confirmation of stent thrombosis is called &quot;definite stent thrombosis&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any Bleeding Event</measure>
    <time_frame>30days</time_frame>
    <description>Bleeding classified by the TIMI hemorrhage classification scheme:
Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to &lt; 5 g/dL
Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of &gt; 5 g/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probable Stent Thrombosis</measure>
    <time_frame>30days</time_frame>
    <description>Probable stent thrombosis is considered to have occurred in case of
any unexplained death within the first 30 days.
any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1008</enrollment>
  <condition>Platelet Inhibition</condition>
  <condition>Coronary Stent Implantation</condition>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>individualized therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel or ticagrelor</intervention_name>
    <description>prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month</description>
    <arm_group_label>individualized therapy</arm_group_label>
    <other_name>Efient</other_name>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>clopidogrel 75mg od for 12 month</description>
    <arm_group_label>standard therapy</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all consecutive PCI patients with stent implantation of our institution

        Exclusion Criteria:

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenter Christ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Franz Josef Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.multiplate.net</url>
  </link>
  <reference>
    <citation>Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030.</citation>
    <PMID>19264241</PMID>
  </reference>
  <reference>
    <citation>Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008 Apr 8;51(14):1404-11. doi: 10.1016/j.jacc.2007.12.044.</citation>
    <PMID>18387444</PMID>
  </reference>
  <reference>
    <citation>Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290. Erratum in: JAMA. 2011 Jun 1;305(21);2174. Stillablower, Michael E [corrected to Stillabower, Michael E].</citation>
    <PMID>21406646</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>February 3, 2013</results_first_submitted>
  <results_first_submitted_qc>March 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2013</results_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaiser Franz Josef Hospital</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Guenter Christ</investigator_full_name>
    <investigator_title>Univ. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>clopidogrel-nonresponder</keyword>
  <keyword>stent thrombosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>all consecutive PCI patients with stent implantation or drug eluting balloon dilation in our institution until June 2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Therapy</title>
          <description>standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)</description>
        </group>
        <group group_id="P2">
          <title>Individualized Therapy</title>
          <description>dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="665"/>
                <participants group_id="P2" count="343"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="664"/>
                <participants group_id="P2" count="343"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Therapy</title>
          <description>standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)</description>
        </group>
        <group group_id="B2">
          <title>Individualized Therapy</title>
          <description>dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="665"/>
            <count group_id="B2" value="343"/>
            <count group_id="B3" value="1008"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="502"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="12"/>
                    <measurement group_id="B2" value="64" spread="12"/>
                    <measurement group_id="B3" value="65" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="482"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="665"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="1008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Definite Stent Thrombosis</title>
        <description>The angiographic or pathological confirmation of stent thrombosis is called &quot;definite stent thrombosis&quot;</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy</title>
            <description>standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)</description>
          </group>
          <group group_id="O2">
            <title>Individualized Therapy</title>
            <description>dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer</description>
          </group>
        </group_list>
        <measure>
          <title>Definite Stent Thrombosis</title>
          <description>The angiographic or pathological confirmation of stent thrombosis is called &quot;definite stent thrombosis&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Any Bleeding Event</title>
        <description>Bleeding classified by the TIMI hemorrhage classification scheme:
Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to &lt; 5 g/dL
Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of &gt; 5 g/dL</description>
        <time_frame>30days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy</title>
            <description>standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)</description>
          </group>
          <group group_id="O2">
            <title>Individualized Therapy</title>
            <description>dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer</description>
          </group>
        </group_list>
        <measure>
          <title>Any Bleeding Event</title>
          <description>Bleeding classified by the TIMI hemorrhage classification scheme:
Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to &lt; 5 g/dL
Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of &gt; 5 g/dL</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probable Stent Thrombosis</title>
        <description>Probable stent thrombosis is considered to have occurred in case of
any unexplained death within the first 30 days.
any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure</description>
        <time_frame>30days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy</title>
            <description>standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)</description>
          </group>
          <group group_id="O2">
            <title>Individualized Therapy</title>
            <description>dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer</description>
          </group>
        </group_list>
        <measure>
          <title>Probable Stent Thrombosis</title>
          <description>Probable stent thrombosis is considered to have occurred in case of
any unexplained death within the first 30 days.
any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>it was not intended to collect adverse events, other than SAEs</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Therapy</title>
          <description>standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)</description>
        </group>
        <group group_id="E2">
          <title>Individualized Therapy</title>
          <description>dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="664"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Definite stentthrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="664"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>probable Stentthrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="664"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiovascular death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="664"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Bleeding (TIMI major)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="664"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Bleeding (TIMI minor)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="664"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Univ.Prof. Dr Günter Christ</name_or_title>
      <organization>Kaiser Franz Josef Hospital</organization>
      <phone>+43160191 ext 2508</phone>
      <email>guenter.christ@wienkav.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

